올라넥시딘

개요In July 2015, olanexidine gluconate, a biguanide compound with remarkable antibacterial activity, was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for skin antisepsis at surgical sites. The drug was developed and marketed by Otsuka Pharmaceutical in Japan and is available as topical solution (1.5%). Olanexidine gluconate exhibited efficacy against a wide range of bacterial strains, especially Grampositive bacteria. In vitro experiments exploring its mechanism of action indicated that olanexidine interacts with bacterial surface molecules (such as lipopolysaccharides and lipoteichoic acid), disrupting the cell membranes of liposomes. These models suggest that the drug permeates the membranes of both Escherichia coli and Staphylococcus aureus and denatures proteins at relatively high concentrations (>160 g/mL).